



OPEN

## Nasopharyngeal microbiota in hospitalized children with *Bordetella pertussis* and Rhinovirus infection

A. E. Tozzi<sup>1</sup>, F. Del Chierico<sup>2,7</sup>✉, E. Pandolfi<sup>1,7</sup>, S. Reddel<sup>2</sup>, F. Gesualdo<sup>1</sup>, S. Gardini<sup>3</sup>, V. Guarrasi<sup>3</sup>, L. Russo<sup>1</sup>, I. Croci<sup>1</sup>, I. Campagna<sup>1</sup>, G. Linardos<sup>4</sup>, C. Concato<sup>4</sup>, A. Villani<sup>5</sup> & L. Putignani<sup>6</sup>✉

Despite great advances in describing *Bordetella pertussis* infection, the role of the host microbiota in pertussis pathogenesis remains unexplored. Indeed, the microbiota plays important role in defending against bacterial and viral respiratory infections. We investigated the nasopharyngeal microbiota in infants infected by *B. pertussis* (Bp), Rhinovirus (Rv) and simultaneously by both infectious agents (Bp + Rv). We demonstrated a specific nasopharyngeal microbiome profiles for Bp group, compared to Rv and Bp + Rv groups, and a reduction of microbial richness during coinfection compared to the single infections. The comparison amongst the three groups showed the increase of Alcaligenaceae and *Achromobacter* in Bp and Moraxellaceae and *Moraxella* in Rv group. Furthermore, correlation analysis between patients' features and nasopharyngeal microbiota profile highlighted a link between delivery and feeding modality, antibiotic administration and *B. pertussis* infection. A model classification demonstrated a microbiota fingerprinting specific of Bp and Rv infections. In conclusion, external factors since the first moments of life contribute to the alteration of nasopharyngeal microbiota, indeed increasing the susceptibility of the host to the pathogens' infections. When the infection is triggered, the presence of infectious agents modifies the microbiota favoring the overgrowth of commensal bacteria that turn in pathobionts, hence contributing to the disease severity.

The nasopharyngeal tract is inhabited by specific ecosystems that may change during infections<sup>1–4</sup> and that play a central role in the host's susceptibility to pathogens<sup>5</sup>. However, as the microbiota in this district is strongly influenced by the environment, its microbial ecology and the interactions with pathogens are of particular interest in full comprehension of diseases.

*Bordetella pertussis* is the main causative agent of pertussis, a highly contagious respiratory infectious disease that continues to occur worldwide, in both highly vaccinated and unvaccinated populations<sup>6</sup>. Pertussis is still a major cause of morbidity and mortality in infants and children < 5 years old<sup>7</sup>. It is estimated that ~ 53,500 (0.9%) of the 5.941 million deaths in 2015 were due to pertussis in this age group<sup>8</sup>.

A significant proportion of pertussis infections presents with a concomitant viral infection, mostly represented by rhinoviruses<sup>9,10</sup>. While the clinical significance and pathogenesis of coinfections are not definitely clarified yet, either *B. pertussis* and rhinovirus infections in infancy have been associated with wheezing and asthma in

<sup>1</sup>Multifactorial Disease and Complex Phenotype Research Area, Bambino Gesù Children's Hospital, IRCCS, Piazza S. Onofrio, 4, 00165 Rome, Italy. <sup>2</sup>Multimodal Laboratory Medicine Research Area, Unit of Human Microbiome, Bambino Gesù Children's Hospital, IRCCS, Viale di San Paolo, 15, 00146 Rome, Italy. <sup>3</sup>GenomeUp SRL, Viale Pasteur, 6, 00144 Rome, Italy. <sup>4</sup>Department of Diagnostic and Laboratory Medicine, Unit of Microbiology and Diagnostic Immunology, Unit of Virology, Bambino Gesù Children's Hospital, IRCCS, Piazza S. Onofrio, 4, 00165 Rome, Italy. <sup>5</sup>Department of Pediatrics, Bambino Gesù Children's Hospital, IRCCS, Piazza S. Onofrio, 4, 00165 Rome, Italy. <sup>6</sup>Department of Diagnostic and Laboratory Medicine, Unit of Microbiology and Diagnostic Immunology, Unit of Microbiomics and Multimodal Laboratory Medicine Research Area, Unit of Human Microbiome, Bambino Gesù Children's Hospital, IRCCS, Piazza S. Onofrio, 4, 00165 Rome, Italy. <sup>7</sup>These authors contributed equally: F. Del Chierico and E. Pandolfi. ✉email: federica.delchierico@opbg.net; lorenza.putignani@opbg.net

	Total (n = 54)	<i>B. pertussis</i> (n = 15)	Rhinovirus (n = 18)	Coinfection (n = 21)	p value
	n (%)	n (%)	n (%)	n (%)	
Males	31 (57.4)	9 (60.0)	10 (55.6)	12 (57.1)	0.967
Age (months)					
Median (IQR)	1.5 (1–3)	2.0 (1–3)	1.0 (1–2)	1.0 (1–3)	0.602
Gestational age (weeks)					
Median (IQR)	38 (37–40)	40 (37–41)	38 (37–38)	39 (38–40)	0.325
Gestational age*					
Preterm born (34–36 weeks)	10 (18.9)	3 (20.0)	4 (22.2)	3 (15.0)	0.844
Term born (37–42 weeks)	43 (81.1)	12 (80.0)	14 (77.8)	17 (85.0)	
Weight (kg)					
Median (IQR)	3.3 (3.0–3.5)	3.4 (3.1–3.7)	3.1 (3.0–3.5)	3.3 (3.0–3.5)	0.415
Type of delivery*					
Vaginal	27 (50.9)	6 (40.0)	9 (50.0)	12 (60.0)	0.501
Caesarean	26 (49.1)	9 (60.0)	9 (50.0)	8 (40.0)	
Type of feeding*					
Exclusive maternal	23 (43.4)	2 (14.3)	9 (50.0)	12 (57.1)	0.029
Mixed	13 (24.5)	3 (21.4)	4 (22.2)	6 (28.6)	
Formula	17 (32.1)	9 (64.3)	5 (27.8)	3 (14.3)	

**Table 1.** Characteristics of the patients (n = 54). \*missing values for 1 patient.

older ages<sup>11,12</sup>. The pathogenesis of asthma episodes may involve the ecology of the respiratory tract as suggested by some authors<sup>3,13,14</sup>.

Modulation of the nasopharyngeal microbiota in the presence of *B. pertussis* infection has been described in the mouse models only<sup>15,16</sup>. These studies evidenced a preventive action of the nasopharyngeal resident microbiota against *B. pertussis* colonization<sup>15</sup>, while the use of antibiotics produces the opposite effect, favoring *B. pertussis* colonization<sup>16</sup>.

Understanding the modulation of ecology of nasopharynx in humans with *B. pertussis* infection may help to understand determinants and potential diagnostic, preventive and therapeutic implications for this disease. In addition, no data are available on the changes that may derive from the simultaneous infection by *B. pertussis* and Rhinovirus.

In this study, we investigated the characteristics of nasopharyngeal microbiome in infants with *B. pertussis* and Rhinovirus simultaneous infection with those of either infection alone.

## Results

**Patients' clinical features.** Socio-demographic characteristics of patients included in the study are shown in Table 1.

The majority of patients were males (57.4%) with a median age of 1.5 months; patients with *B. pertussis* infection were slightly older than those with Rhinovirus infection or coinfection.

Children with coinfection were more likely breastfed compared to those with Rhinovirus even if the difference is small (57% vs 50% respectively,  $p = 0.029$ ). On the other hand, children with *B. pertussis* infection were more likely formula-fed compared to those with coinfection (64% vs 14%,  $p = 0.029$ ).

Table 2 shows the clinical features among the three groups. Cough, paroxysmal cough, whooping and apnea were more frequent in patients with *B. pertussis* infection. Cyanosis was occurred more frequently in the coinfection group by comparison to the Bp or Rv groups. In addition, the coinfection group more likely uses antibiotics before admission.

Dendrogram analysis, based on clinical features' correlation, revealed that C-reactive protein (CRP), fever and antibiotic treatment at the admission (others' than macrolides) were correlated together and constituted a separated cluster from the other clinical variables. The other features were subgrouped into: (i) apnea, cyanosis, macrolides' assumption and antibiotics treatment before the admission, and (ii) delivery, feeding cough, paroxysmal cough and inspiratory stridor, complications, vomit and leukocytes plus lymphocytes count (Fig. S1).

**Nasopharyngeal microbiota profiling.** A total of 2,393,694 sequencing reads were obtained from 54 nasopharyngeal aspirates, with a mean value of 44,328 sequences per sample. We identified an overall of 245 operational taxonomic units (OTUs), belonging to 15 phyla and 95 families.

To assess the overall differences of microbial community structures for the three groups, ecological parameters were based on alpha-diversity indexes (*i.e.*, Shannon, Chao1, and Observed species indexes).

Despite no statistical differences were resulted, samples belonging to Rv group showed higher values of all indexes followed by Bp samples and then Bp + Rv samples (Fig. 1, panels a–c).

Regarding beta diversity analysis, only Bray Curtis algorithm evidenced a statistically significant separation amongst groups (PERMANOVA  $p$  value  $\leq 0.05$ ), while phylogenetic unweighted and weighted UniFrac algorithms not (PERMANOVA  $p$  values  $> 0.05$ ) (Fig. 1, panels d–f). Analyses of the intra-group distances revealed

	Total (n = 54)		<i>B. pertussis</i> (n = 15)		Rhinovirus (n = 18)		Coinfection (n = 21)		p value
	n	%	n	%	n	%	n	%	
Cough	45	83.3	15	100.0	11	61.1	19	90.5	0.006
Cyanosis	28	51.9	9	60.0	5	27.8	14	66.7	0.040
Vomit	22	40.7	5	33.3	7	38.9	10	47.6	0.678
Paroxysmal cough	32	59.3	14	93.3	2	11.1	16	76.2	<0.001
Apnea	30	55.6	11	73.3	5	27.8	14	66.7	0.014
Fever	12	22.2	1	6.7	6	33.3	5	23.8	0.181
Whooping	24	44.4	11	73.3	0	–	13	61.9	<0.001
Antibiotics before admission	13	25.0	4	28.6	1	5.6	8	40.0	0.047
<b>Antibiotics at admission</b>									
No antibiotic	12	22.2	1	6.7	9	50.0	2	9.5	<0.001
Macrolides	35	64.8	13	86.7	3	16.7	19	90.5	
Other	7	13.0	1	6.7	6	33.3	0	–	
Leukocytes plus lymphocytes*	18	35.3	5	33.3	3	17.7	10	52.6	0.089
Complications	7	13.0	3	20.0	1	5.6	3	14.3	0.457
C-Reactive Protein (CRP)	23	43.4	5	33.3	10	55.6	8	40.0	0.407

**Table 2.** Clinical features by group of infection (n = 54). \*White cell count > max for age and lymphocytes > 50%.

statistically significant differences between Bp and Rv for Bray–Curtis and Unweighted UniFrac metrics (Fig. 1, panels g–i).

The OTU distribution was investigated at the phylum and genus levels. At phylum level, Proteobacteria, Firmicutes, Actinobacteria and Bacteroidetes were the most representative phyla in the three groups (Fig. S2, Panel A). At genus level, Enterobacteriaceae, *Veillonella*, *Staphylococcus*, Gemellaceae, Alcaligenaceae and *Achromobacter* were increased in Bp ecosystem, while *Streptococcus* and *Moraxella* in Rv group (Fig. S2, Panel B).

Kruskal–Wallis test confirmed the higher abundance of *Achromobacter* and Alcaligenaceae in Bp group compared to the other groups (raw *p* value < 0.05) (Fig. 1, panels j and k), and the higher abundance of *Moraxella* and Moraxellaceae in Rv compared with others (raw *p* value < 0.05) (Fig. 1, panels l and m).

In the comparison amongst the three groups the principal component analysis (PCA) (Fig. S3, Panel a) and the partial least square (PLS) (Fig. S3, Panel b) analyses, performed on OTU's profiles at genus levels, revealed a more separated Bp clusters compared to the other two groups. The same analyses, restricted to Bp and Rv comparison, revealed two separated PCA clusters (Fig. S3, Panel c) and none in PLS (Fig. S3, Panel d).


**Correlation between clinical features and nasopharyngeal microbiota global distribution.** At family level, Pearson's correlation revealed that all considered clinical features showed a correlation with a least one OTU. In particular, Alcaligenaceae was positively correlated with cough, paroxysmal cough and inspiratory stridor, while negatively with CRP. Moraxellaceae was negatively correlated with paroxysmal cough and inspiratory stridor (Fig. 2, panel a).

At genus level, antibiotic treatment before the admission was positively correlated with *Paracoccus* and *Haemophilus* and negatively with *Rothia*. Cough was negatively correlated with *Clostridium*, *Blautia*, *Staphylococcus* and *Ruminococcus* and positively with *Achromobacter*.

Paroxysmal cough was positively correlated with *Neisseria* and *Achromobacter* and negatively with *Moraxella*. Inspiratory stridor was positively correlated with *Campylobacter* and *Achromobacter* and negatively with *Blautia*, *Enterococcus* and *Moraxella*. Cyanosis was negatively correlated with *Aggregatibacter*. Apnea was positively correlated with *Prevotella*, *Neisseria*, *Fusobacterium* and *Porphyromonas* and negatively with *Bacteroides*, *Oscillospira*, *Bifidobacterium* and *Rothia*. CRP had positive correlation with *Haemophilus* and negative with *Achromobacter*. Finally, complications were positively related with *Methanobrevibacter* and *Streptococcus* (Fig. 2, panel b).


**Comparison between Bp- and Rv-related microbiota and patients' clinical profiles.** To focus onto microbiota specific features associated to *B. pertussis* or Rhinovirus infection and to highlight their correlations with patients' clinical traits, we focalized on Bp- and Rv-related microbiota, excluding the coinfection group (Bp + Rv).

The Pearson's correlation performed on OTU profiles at genus level revealed two wide clusters. The first (a) was associated to Rv patients (9/16) with a nasopharyngeal microbiota profile rich in genera belonging to Actinobacteria, Bacteroidetes, Firmicutes and Proteobacteria, and related to low levels of leukocytes + lymphocytes (14/16) (Fig. 3). The second (b) was composed by two sub-clusters, namely  $b_1$  and  $b_2$ . The cluster  $b_1$  was prevalently associated to Bp patients (6/7), characterized by high levels of leukocytes and lymphocytes, Caesarian section delivery and formula milk or mixed milk feeding and by a nasopharyngeal microbiota principally composed by Proteobacteria (Fig. 3). The patients in cluster  $b_2$ , mostly Rv infected, was characterized by low level




**Figure 1.** Microbiota diversity analysis. Alpha diversity analysis (a–c). Box plots show Shannon, Chao1, and Observed species indexes for each patients’ group. Microbiota beta diversity analysis (d–f). Principal coordinates analysis (PCoA) plot of bacterial beta-diversity based on Bray-Curtis dissimilarity (d) and unweighted (e) and weighted (f) UniFrac phylogenetic distance. The plots show the first two principal coordinates (axes) of PCoA. Beta diversity distance box plots (g–i). Data are expressed as minimum, maximum and median values, and 25th and 75th percentiles values. The statistical significant differences are determined by permanova-pairwise tests and indicated by the star. Box plots of OTUs statistically significant by Kruskal–Wallis test (j–m). In y-axis are reported OTU’s relative abundances; in x-axis are reported median, minimum and maximum values, and the 25th and 75th percentile values.





**Figure 3.** Hierarchical cluster of Bp and Rv patients according to OTU distribution at the genus level. The heatmap reports the hierarchical Ward-linkage clustering based on the Pearson’s correlation coefficient amongst OTUs at genus level. The color scale represents the scaled level of each variable: yellow, high level; blue, low level. The column bar is colored according to the subject category and clinical features’ groups. The left bar is colored according to the phylum level taxonomy.



**Figure 4.** Important OTUs selected by model classification analysis. The bars represent the importance scores of each OTUs in the prediction of models.

Bp patients took macrolides (87.6%), then the difference in microbiota diversity with coinfecting patients could be driven by the different type of infection.

Analyzing the distance matrices and the composition of the microbiota, the co-infected microbiota profile was similar to both single infections' microbiota, even if with a higher similarity to the Rv group.

The comparison amongst the three groups revealed the increase of *Alcaligenaceae* and *Achromobacter* in the Bp infection group. *Achromobacter* spp., belonging to *Alcaligenaceae* family, are environmental microorganisms, causing a series of opportunistic illnesses, including respiratory diseases<sup>25,26</sup>. In our study, *Achromobacter* resulted related to cough, paroxysmal cough and inspiratory stridor, suggesting a role of this microorganism in the disease prognosis. Moreover, *Moraxellaceae* and *Moraxella* were increased in Rv infection group, as confirmed also by literature<sup>27–29</sup>. During Rv infection it has been described a colonization by *S. pneumoniae*, *H. influenzae* and *M. catarrhalis*<sup>3,13,30</sup>. In particular, it seems that the nasopharyngeal colonization by *Streptococcus* and *Moraxella* precedes the Rv infection, probably due to the decreasing in ciliary function of epithelial cells and increasing of pro-inflammatory molecule release<sup>30</sup>. The simultaneous presence of Rv and *Moraxella* seems to be associated with severe lower respiratory infections, suggesting a correlation between specific viral/bacterial interactions and increase of disease severity<sup>3</sup>.

Evaluating the impact of delivery and feeding modality, count of leukocytes, administration of antibiotics it was possible to identify specific taxa as representative of Rv and Bp groups. Particularly, patients with vaginal delivery, maternal feeding, low count of leukocytes plus lymphocytes, low administration of antibiotics and rich microbiota profile resulted those infected by Rhinovirus. On the contrary, patients infected by *B. pertussis* were characterized by caesarian section delivery, formula milk feeding, high counts of leukocytes, antibiotic administration and high level of Proteobacteria. Thanks to these evidences we speculate that these conditions could shape the microbiota to be more prone to the airway infection by *B. pertussis*.

In conclusion, external factors since the first moments of life contribute to the alteration of nasopharyngeal microbiota, and this event could increase the susceptibility of the host to the pathogens' infections. In our opinion, when the infection is triggered, the presence of infectious agents could further modify the microbiota ecological niche favoring the overgrowth of other commensal bacteria that turn in pathobionts, hence contributing to the disease severity.

## Methods

**Study design and population.** This study was performed at Bambino Gesù Children's Hospital (OPBG), of Rome, Italy. From January 2016 to December 2019, all infants younger than 1 year of age, accessing the emergency room with symptoms compatible with pertussis, according to European Centre for Disease Prevention and Control (ECDC) case definition, were routinely screened for pertussis and respiratory viruses in the context of an enhanced surveillance program. A subset of patients with either *B. pertussis* (Bp) or Rhinovirus (Rv) or both infections (Bp + Rv), for whom a leftover of the nasopharyngeal aspirate was available for the analysis of the pharynx microbiota, was selected for this study. The study was conducted in accordance with the Declaration

of Helsinki, and the protocol was approved by Bambino Gesù Children's Hospital Ethics Committee (1355\_OPBG2017). Informed consent was obtained from the parents or legal guardians of all participants.

**Data collection and laboratory confirmation of pertussis.** Sociodemographic and clinical data were collected for each patient. Nasopharyngeal aspirate were collected within 24 h of hospital admission and processed immediately, or stored at  $-80^{\circ}\text{C}$  until analysis. Two-hundred  $\mu\text{l}$  of nasopharyngeal sample were used for nucleic acids extraction by the EZ1 Virus Mini Kit v. 2.0 on the EZ1 Advanced XL platform (Qiagen, GmbH, Hilden, Germany).

Bordetella Real Time (RT) PCR kits were used to investigate the presence of *B. pertussis*, amplifying the inter-space (IS) 481 target (Bordetella R-gene™ assay; Argene, Biomerieux, Marcy l'Etoile, France). To prevent misdiagnosis of *Bordetella holmesii* as *B. pertussis*, all samples positive for *B. pertussis* were confirmed by the amplification of *ptxP* (promoter of pertussis toxin) locus by a RT-PCR assay specific for *B. pertussis*. Moreover, culture for *B. pertussis* was also performed, using Regan-Lowe and Bordet-Gengou selective culture media at  $37^{\circ}\text{C}$  under aerobic conditions. Nasopharyngeal aspirates were also processed by a multiplex RT-PCR using a specific panel detecting the 16 following viruses: Respiratory syncytial virus (RSV) A and B; Influenza virus A and B; Coronaviruses OC43, 229E, cNL63, and HUK1; adenovirus; human Rhinovirus (hRV); parainfluenza virus 1–2–3–4; human Metapneumovirus-hMPV and human Bocavirus-hBoV.

**16S rRNA targeted-metagenomics of nasopharyngeal microbiota.** DNA from 200  $\mu\text{l}$  of nasopharyngeal samples was automatically extracted using the EZ1 DNA Tissue Kit and biorobot EZ1 extractor following manufacturer's instructions (Qiagen, Hilden, Germany). The V3-V4 region of 16S rRNA gene (~460 bp) was amplified by PCR using the primers 16S\_F 5'-(TCG TCG GCA GCG TCA GAT GTG TAT AAG AGA CAG CCT ACG GGN GGC WGC AG)-3' and 16S\_R 5'-(GTC TCG TGG GCT CGG AGA TGT GTA TAA GAG ACA GGA CTA CHV GGG TAT CTA ATC C)-3' as reported in the MiSeq rRNA Amplicon Sequencing protocol (Illumina, San Diego, CA). The first amplification was carried out setting up the following conditions: initial denaturation at  $95^{\circ}\text{C}$  for 3 min, 32 cycles of denaturation at  $95^{\circ}\text{C}$  for 30 s, annealing at  $55^{\circ}\text{C}$  for 30 s, and extension at  $72^{\circ}\text{C}$  for 30 s, and a final extension step at  $72^{\circ}\text{C}$  for 5 min, with Fast Start Hifi Taq kit (Roche Diagnostics, Mannheim, Germany). DNA amplicons were cleaned with 20  $\mu\text{l}$  of KAPA Pure Beads (Roche Diagnostics, Mannheim, Germany) and tagged with unique index combinations using Nextera technology in a second amplification step. Following steps consisted of cleaning of the final library, quantification with Quant-iT™ PicoGreen® dsDNA Assay Kit (Thermo Fisher Scientific, Waltham, MA) and dilution to 4 nM concentrations. Pooling, denaturation and dilution to 7 pM were performed before the sequencing on an Illumina MiSeq™ platform (Illumina, San Diego, CA, United States) where paired-end reads of 300 base-length were generated.

All raw sequences have been archived in NCBI database: PRJNA730698 (<https://www.ncbi.nlm.nih.gov/bioproject>).

**Biocomputational and statistical analyses.** Illumina Miseq reads were checked for quality, length and chimera presence using the Qiime v1.9 pipeline<sup>31</sup>, and USEARCH algorithms<sup>32</sup>. Then, sequences were organized into Operational Taxonomic Units (OTUs) with a 97% of clustering threshold of pairwise identity by UCLUST with open reference method<sup>32</sup>. PyNAST v.0.1 software<sup>31</sup> was used to carry out a multiple sequence alignment against Greengenes 13\_08 database with a 97% similarity for bacterial sequences and to build a phylogenetic tree<sup>33</sup>. Alpha diversity was performed by scikit-bio (<http://scikit-bio.org/>) of Python 3 package using Shannon index, Chao1 estimator, and observed species indices, and the *p* value for group comparisons was determined by analysis of variance (ANOVA). Beta diversity analysis of samples, based on phylogenetically informed weighted and unweighted Unifrac distance matrices<sup>34</sup> and Bray Curtis matrices, was used and graphed by principal coordinate analysis (PCoA) plots. The association between the covariates and beta diversity measures was assessed by permutational analysis of variance (PERMANOVA)<sup>35</sup>.

Categorical variables were tabulated as frequencies and percentages and compared using Pearson's Chi square test.

OTUs were filtered to select only the features of interest by retaining OTUs with interquartile range (IQR)  $\neq 0$  and OTUs present in at least 25% of the samples.

The non-parametric Mann-Whitney U-test, Wilcoxon signed-rank, Kruskal-Wallis test, corrected for FDR *p* value  $\leq 0.05$ , were used to compare OTUs relative abundance amongst groups.

Both the OTUs and clinical variables (considered both raw values and categorical variables) were clustered using the Pearson's correlation coefficient as the distance measure. In order to correlate clinical variables and OTUs, the Pearson's coefficient with relative *p* value was calculated and represented by heat map.

Multiple machine learning (ML) was trained for the classification tasks. The pipeline consisted of a tenfold cross-validation with a train-test split of 70–30%. To evaluate the model, the global and the single class accuracies were considered. The tested models were: Logistic Regression, SGD Classifier, Logistic Regression CV, Hist Gradient Boosting Classifier, Random Forest Classifier, Extra Trees Classifier, Gradient Boosting Classifier, Bagging Classifier, Ada Boost Classifier, XGB Classifier, XGBRF Classifier, MLP Classifier, Linear SVC, SVC, Gaussian NB, Decision Tree Classifier, Quadratic Discriminant Analysis, K Neighbors Classifier, Gaussian Process Classifier.

Received: 9 July 2021; Accepted: 7 November 2021

Published online: 24 November 2021



## References

- Jones, N. The nose and paranasal sinuses physiology and anatomy. *Adv. Drug Deliv. Rev.* **51**, 5–19 (2001).
- Yan, M. *et al.* Nasal microenvironments and interspecific interactions influence nasal microbiota complexity and *S. aureus* carriage. *Cell Host Microbe* **14**, 631–640 (2013).
- Teo, S. M. *et al.* The infant nasopharyngeal microbiome impacts severity of lower respiratory infection and risk of asthma development. *Cell Host Microbe* **17**, 704–715 (2015).
- Iorio, A. *et al.* Cross-correlation of virome–bacteriome–host–metabolome to study respiratory health. *Trends Microbiol.* S0966842X21001220 (2021) <https://doi.org/10.1016/j.tim.2021.04.011>.
- Liu, C. M. *et al.* *Staphylococcus aureus* and the ecology of the nasal microbiome. *Sci. Adv.* **1**, e1400216 (2015).
- Forsyth, K. D. *et al.* Recommendations to control pertussis prioritized relative to economics: A Global Pertussis Initiative update. *Vaccine* **36**, 7270–7275 (2018).
- Pertussis vaccines: WHO position paper - September 2015. *Wkly. Epidemiol. Rec.* **90**, 433–458 (2015).
- Liu, L. *et al.* Global, regional, and national causes of under-5 mortality in 2000–15: An updated systematic analysis with implications for the Sustainable Development Goals. *Lancet* **388**, 3027–3035 (2016).
- Frassanito, A. *et al.* Infants hospitalized for *Bordetella pertussis* infection commonly have respiratory viral coinfections. *BMC Infect. Dis.* **17**, 492 (2017).
- Pandolfi, E. *et al.* Cytokine expression patterns in hospitalized children with *Bordetella pertussis*, Rhinovirus or co-infection. *Sci. Rep.* **11**, 10948 (2021).
- Rubin, K. & Glazer, S. The pertussis hypothesis: *Bordetella pertussis* colonization in the etiology of asthma and diseases of allergic sensitization. *Med. Hypotheses* **120**, 101–115 (2018).
- Han, M., Rajput, C. & Hershenson, M. B. Rhinovirus attributes that contribute to asthma development. *Immunol. Allergy Clin. N. Am.* **39**, 345–359 (2019).
- Mansbach, J. M. *et al.* Respiratory syncytial virus and rhinovirus severe bronchiolitis are associated with distinct nasopharyngeal microbiota. *J. Allergy Clin. Immunol.* **137**, 1909–1913.e4 (2016).
- Chun, Y. *et al.* Integrative study of the upper and lower airway microbiome and transcriptome in asthma. *JCI Insight* **5**, (2020).
- Weyrich, L. S. *et al.* Resident microbiota affect *Bordetella pertussis* infectious dose and host specificity. *J. Infect. Dis.* **209**, 913–921 (2014).
- Zhang, Y. *et al.* Commensal microbes affect host humoral immunity to *Bordetella pertussis* infection. *Infect. Immun.* **87**, e00421–e519. <https://doi.org/10.1128/IAI.00421-19> (2019).
- Bogaert, D. *et al.* Variability and diversity of nasopharyngeal microbiota in children: A metagenomic analysis. *PLoS ONE* **6**, e17035 (2011).
- García-Rodríguez, J. A. & Fresnadillo Martínez, M. J. Dynamics of nasopharyngeal colonization by potential respiratory pathogens. *J. Antimicrob. Chemother.* **50**(Suppl S2), 59–73 (2002).
- Chi, D. H. *et al.* Nasopharyngeal reservoir of bacterial otitis media and sinusitis pathogens in adults during wellness and viral respiratory illness. *Am. J. Rhinol.* **17**, 209–214 (2003).
- Sevillano, D. *et al.* Beta-lactam effects on mixed cultures of common respiratory isolates as an approach to treatment effects on nasopharyngeal bacterial population dynamics. *PLoS ONE* **3**, e3846 (2008).
- Pelton, S. I. Regulation of bacterial trafficking in the nasopharynx. *Paediatr. Respir. Rev.* **13**, 150–153 (2012).
- Allen, E. K. *et al.* Characterization of the nasopharyngeal microbiota in health and during rhinovirus challenge. *Microbiome* **2**, 22 (2014).
- Brogden, K. A., Guthmiller, J. M. & Taylor, C. E. Human polymicrobial infections. *Lancet* **365**, 253–255 (2005).
- Dubourg, G., Edouard, S. & Raoult, D. Relationship between nasopharyngeal microbiota and patient's susceptibility to viral infection. *Expert Rev. Anti Infect. Ther.* **17**, 437–447 (2019).
- De Baets, F. *et al.* *Achromobacter xylosoxidans* induced bronchiolitis obliterans in cystic fibrosis. *Pediatr. Pulmonol.* **49**, 414–416 (2014).
- Trancassini, M. *et al.* Outbreak of *Achromobacter xylosoxidans* in an Italian Cystic fibrosis center: Genome variability, biofilm production, antibiotic resistance, and motility in isolated strains. *Front. Microbiol.* **5**, 138 (2014).
- de Steenhuijsen Piters, W. A. A., Binkowska, J. & Bogaert, D. Early life microbiota and respiratory tract infections. *Cell Host Microbe* **28**, 223–232 (2020).
- Neumann, R. P. *et al.* Nasal microbiota and symptom persistence in acute respiratory tract infections in infants. *ERJ Open Res.* **4**, 00066–02018 (2018).
- Lapidot, R. *et al.* 2628. Nasopharyngeal microbiome in the first weeks of life distinguishes infants who subsequently develop lower respiratory tract infections. *Open Forum Infect. Dis.* **6**, S917–S917 (2019).
- Kloepfer, K. M. *et al.* Detection of pathogenic bacteria during rhinovirus infection is associated with increased respiratory symptoms and asthma exacerbations. *J. Allergy Clin. Immunol.* **133**(1301–1307), 1307.e1–3 (2014).
- Caporaso, J. G. *et al.* QIIME allows analysis of high-throughput community sequencing data. *Nat. Methods* **7**, 335–336 (2010).
- Edgar, R. C. Search and clustering orders of magnitude faster than BLAST. *Bioinformatics* **26**, 2460–2461 (2010).
- DeSantis, T. Z., Dubosarskiy, I., Murray, S. R. & Andersen, G. L. Comprehensive aligned sequence construction for automated design of effective probes (CASCADE-P) using 16S rDNA. *Bioinformatics* **19**, 1461–1468 (2003).
- Lozupone, C. & Knight, R. UniFrac: A new phylogenetic method for comparing microbial communities. *AEM* **71**, 8228–8235 (2005).
- Chen, J. *et al.* Associating microbiome composition with environmental covariates using generalized UniFrac distances. *Bioinformatics* **28**, 2106–2113 (2012).

## Acknowledgements

This work was supported by the Italian Ministry of Health (Ricerca Corrente 2016, 2017, 2018, 2019 and 5% 2020, assigned to LP).

## Author contributions

Conceptualization, A.E.T.; and L.P.; methodology, F.D.C., S.R. and G.L.; formal analysis, F.D.C., S.G. and V.G.; investigation, E.P., S.R., F.D.C., R.L., I.Ca., I.Cr., C.C., G.F., and V.A.; resources, L.P.; data curation, E.P., S.R., and F.D.C.; writing—original draft preparation, A.E.T.; E.P., S.R. and F.D.C.; writing—review and editing, F.D.C., E.P., I.Cr., A.E.T., and L.P. All authors have read and agreed to the published version of the manuscript.

## Competing interests

The authors declare no competing interests.

### Additional information

**Supplementary Information** The online version contains supplementary material available at <https://doi.org/10.1038/s41598-021-02322-y>.

**Correspondence** and requests for materials should be addressed to F.D.C. or L.P.

**Reprints and permissions information** is available at [www.nature.com/reprints](http://www.nature.com/reprints).

**Publisher's note** Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.



**Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <http://creativecommons.org/licenses/by/4.0/>.

© The Author(s) 2021